RU2007116973A - Терапевтические средства с пониженной токсичностью - Google Patents
Терапевтические средства с пониженной токсичностью Download PDFInfo
- Publication number
- RU2007116973A RU2007116973A RU2007116973/13A RU2007116973A RU2007116973A RU 2007116973 A RU2007116973 A RU 2007116973A RU 2007116973/13 A RU2007116973/13 A RU 2007116973/13A RU 2007116973 A RU2007116973 A RU 2007116973A RU 2007116973 A RU2007116973 A RU 2007116973A
- Authority
- RU
- Russia
- Prior art keywords
- conjugate molecule
- sabm
- molecule according
- amino acid
- seq
- Prior art date
Links
- 230000001988 toxicity Effects 0.000 title claims 4
- 231100000419 toxicity Toxicity 0.000 title claims 4
- 229940126585 therapeutic drug Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 108010052285 Membrane Proteins Proteins 0.000 claims 4
- 102000018697 Membrane Proteins Human genes 0.000 claims 4
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 231100000599 cytotoxic agent Toxicity 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 102000007562 Serum Albumin Human genes 0.000 claims 3
- 108010071390 Serum Albumin Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229920002776 polycyclohexyl methacrylate Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61650704P | 2004-10-05 | 2004-10-05 | |
| US60/616,507 | 2004-10-05 | ||
| US64153405P | 2005-01-05 | 2005-01-05 | |
| US60/641,534 | 2005-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007116973A true RU2007116973A (ru) | 2008-11-20 |
Family
ID=36051453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007116973/13A RU2007116973A (ru) | 2004-10-05 | 2005-09-22 | Терапевтические средства с пониженной токсичностью |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20060073152A1 (enExample) |
| EP (1) | EP1796718A2 (enExample) |
| JP (1) | JP2008515889A (enExample) |
| KR (1) | KR20070073886A (enExample) |
| AU (1) | AU2005294723A1 (enExample) |
| BR (1) | BRPI0516577A (enExample) |
| CA (1) | CA2583137A1 (enExample) |
| IL (1) | IL182261A0 (enExample) |
| MX (1) | MX2007003907A (enExample) |
| RU (1) | RU2007116973A (enExample) |
| WO (1) | WO2006041641A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2357006T1 (sl) | 2002-07-31 | 2016-01-29 | Seattle Genetics, Inc. | Konjugati zdravil in njihova uporaba za zdravljenje raka, avtoimunske bolezni ali infekcijske bolezni |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| EP1817336B1 (en) * | 2004-11-12 | 2019-01-09 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| ES2585357T3 (es) | 2005-07-07 | 2016-10-05 | Seattle Genetics, Inc. | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| US8871720B2 (en) * | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| CL2008002085A1 (es) | 2007-07-16 | 2008-11-21 | Genentech Inc | Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b |
| EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
| US20090035848A1 (en) * | 2007-08-03 | 2009-02-05 | Robert Hickey | Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products |
| CN104650230A (zh) | 2008-01-31 | 2015-05-27 | 健泰科生物技术公司 | 抗cd79b抗体和免疫偶联物及使用方法 |
| CA2718942A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
| EP2513148B1 (en) * | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
| CA2833477A1 (en) * | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
| US20140127713A1 (en) | 2011-06-28 | 2014-05-08 | Femke Karina de Theije | Means for the examination of body fluids |
| WO2013096940A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Double binding constructs |
| EP3013370A1 (en) * | 2013-06-24 | 2016-05-04 | Riogin Corporation | Double binding constructs |
| DK3039038T3 (da) * | 2013-08-30 | 2021-02-08 | Aprilbio Co Ltd | Fusionskonstruktion med antiserumalbumin-fab-effektordel, og fremstillingsmetode dertil |
| EP3262071B8 (en) | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| EP3665202A1 (en) * | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| WO2023092733A1 (zh) * | 2021-11-25 | 2023-06-01 | 苏州慧疗生物医药科技有限公司 | 一种用于有效递送核酸的环状多肽载体及其变化形式 |
| EP4592321A1 (en) * | 2022-09-20 | 2025-07-30 | Biotheus Inc. | Anti-her2 antibodies and use thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3561444A (en) * | 1968-05-22 | 1971-02-09 | Bio Logics Inc | Ultrasonic drug nebulizer |
| US3703173A (en) * | 1970-12-31 | 1972-11-21 | Ted A Dixon | Nebulizer and tent assembly |
| US3862925A (en) * | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) * | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (enExample) * | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) * | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4635627A (en) * | 1984-09-13 | 1987-01-13 | Riker Laboratories, Inc. | Apparatus and method |
| US4624251A (en) * | 1984-09-13 | 1986-11-25 | Riker Laboratories, Inc. | Apparatus for administering a nebulized substance |
| US4970198A (en) * | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
| US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| SE509359C2 (sv) * | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| EP0940468A1 (en) * | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69226197T2 (de) * | 1991-11-08 | 1999-02-11 | Somatogen, Inc., Boulder | Hämoglobine als arzneimittelabgabesystem |
| US5767237A (en) * | 1993-10-01 | 1998-06-16 | Teikoku Hormone Mfg. Co., Ltd. | Peptide derivatives |
| US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5780054A (en) * | 1996-01-17 | 1998-07-14 | University Of British Columbia | Methods for increasing the circulation half-life of protein-based therapeutics |
| US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US6632979B2 (en) * | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US20040018194A1 (en) * | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
| US20050089932A1 (en) * | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| US20030009395A1 (en) * | 2001-07-06 | 2003-01-09 | Yu Philip Shi-Lung | Method and apparatus for providing information regarding a product |
| ES2411007T3 (es) * | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| US7435797B2 (en) * | 2002-04-10 | 2008-10-14 | Genentech, Inc. | Anti-HER2 antibody variants |
| WO2004032828A2 (en) * | 2002-07-31 | 2004-04-22 | Seattle Genetics, Inc. | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| US20040032828A1 (en) * | 2002-08-16 | 2004-02-19 | Cellglide Technologies Corp. | Service management in cellular networks |
| BR122018071808B8 (pt) * | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
-
2005
- 2005-09-22 KR KR1020077010255A patent/KR20070073886A/ko not_active Withdrawn
- 2005-09-22 MX MX2007003907A patent/MX2007003907A/es not_active Application Discontinuation
- 2005-09-22 BR BRPI0516577-6A patent/BRPI0516577A/pt not_active Application Discontinuation
- 2005-09-22 EP EP05810079A patent/EP1796718A2/en not_active Withdrawn
- 2005-09-22 CA CA002583137A patent/CA2583137A1/en not_active Abandoned
- 2005-09-22 AU AU2005294723A patent/AU2005294723A1/en not_active Abandoned
- 2005-09-22 JP JP2007535700A patent/JP2008515889A/ja not_active Withdrawn
- 2005-09-22 WO PCT/US2005/033952 patent/WO2006041641A2/en not_active Ceased
- 2005-09-22 US US11/233,256 patent/US20060073152A1/en not_active Abandoned
- 2005-09-22 RU RU2007116973/13A patent/RU2007116973A/ru not_active Application Discontinuation
-
2006
- 2006-09-25 US US11/535,027 patent/US20090123376A1/en not_active Abandoned
-
2007
- 2007-03-28 IL IL182261A patent/IL182261A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005294723A1 (en) | 2006-04-20 |
| JP2008515889A (ja) | 2008-05-15 |
| MX2007003907A (es) | 2007-05-21 |
| US20090123376A1 (en) | 2009-05-14 |
| US20060073152A1 (en) | 2006-04-06 |
| WO2006041641A2 (en) | 2006-04-20 |
| EP1796718A2 (en) | 2007-06-20 |
| WO2006041641A3 (en) | 2006-06-29 |
| IL182261A0 (en) | 2007-07-24 |
| KR20070073886A (ko) | 2007-07-10 |
| CA2583137A1 (en) | 2006-04-20 |
| BRPI0516577A (pt) | 2008-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007116973A (ru) | Терапевтические средства с пониженной токсичностью | |
| JP7133611B2 (ja) | 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体 | |
| JP7377327B2 (ja) | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート | |
| KR102645430B1 (ko) | 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커 | |
| JP6892826B2 (ja) | Ｃｄ４８抗体及びその複合体 | |
| JP2008515889A5 (enExample) | ||
| RS65978B1 (sr) | Trispecifični proteini i postupci primene | |
| TW201800110A (zh) | 基於艾日布林之抗體－藥物結合物及使用方法 | |
| CN110167968B (zh) | 针对her3的抗原结合蛋白 | |
| TW201709932A (zh) | Ｃｄ１２３抗體及其共軛物 | |
| CN106029083A (zh) | 亲水性抗体-药物偶联物 | |
| BRPI0719597A2 (pt) | Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir | |
| CN112601522A (zh) | 抗体-alk5抑制剂偶联物及其用途 | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| CN114514041A (zh) | 抗ptcra抗体-药物缀合物及其用途 | |
| EP3864039B1 (en) | Neuroendocrine cancer targeted therapy | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 | |
| CN114269388A (zh) | 抗体-alk5抑制剂缀合物及其用途 | |
| EP4587063A1 (en) | Anti-muc1* antibody drug complexes and uses thereof | |
| Auvert et al. | Development of optimized exatecan-based immunoconjugates with potent antitumor efficacy in HER2-positive breast cancer | |
| EP4616869A1 (en) | Fap targeted antibody-drug conjugates | |
| KR20250148459A (ko) | 항-cntn4 항체를 포함하는 컨쥬게이트 및 이의 용도 | |
| KR20250034273A (ko) | 항-도펠 항체-약물 접합체 | |
| CN120957759A (zh) | 具有抗肿瘤作用的化合物及其制备方法和用途 | |
| HK40053532A (en) | Eribulin-based antibody-drug conjugates and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20081107 |